668271-94-1Relevant academic research and scientific papers
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin- 2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
Eckhardt, Matthias,Langkopf, Elke,Mark, Michael,Tadayyon, Moh,Thomas, Leo,Nar, Herbert,Pfrengle, Waldemar,Guth, Brian,Lotz, Ralf,Sieger, Peter,Fuchs, Holger,Himmelsbach, Frank
, p. 6450 - 6453 (2008/04/12)
A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Systematic structural variations have led to 1 (BI 1356), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species. 1 is currently undergoing clinical phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.
8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS
-
Page/Page column 71, (2008/06/13)
The invention relates to substituted xanthines of general formula (I) wherein R1 to R3 have the designations cited in patent claims 1 to 16, and to the tautomers, stereoisomers, mixtures, prodrugs and salts thereof, which have precio
